EndoSound

11/20/2025

https://www.linkedin.com/feed/update/urn:li:activity:7397257483687239681

📽️ 🤵 It's not often you get to know the people behind the curtain. At EndoSound, we're a small group—more like family, really. And like any modern family, we love sharing our stories... so here is Peter Hoffman, Senior Product Development Engineer at EndoSound. Peter has been with us for o...

11/06/2025

https://www.instagram.com/p/DQuI63aD4h9/?utm_source=ig_web_copy_link&igsh=MzRlODBiNWFlZA==

10/27/2025

EndoSound® has reached milestones that few medtech companies achieve this early. With FDA clearance validating safety and effectiveness, reimbursement securing financial viability for providers, and $1M in revenue since launch from real-world use, the company has already demonstrated both clinical and commercial traction.

Investor support reflects the strength of this opportunity. More than $2.M has been committed in the current round by hundreds of investors who see the potential to scale a technology that lowers costs, expands access, and positions EndoSound to transform the $20B GI device market.

The Wefunder campaign is entering its final week.

If you didn't get a chance last time, there is still time to act.

We will end this campaign on November 3rd. Secure your stake now and be part of bringing accessible, life-saving GI technology to patients worldwide.

We are now on Instagram too!! Please come follow us there for more updates and behind-the-scenes progress.

10/16/2025

https://www.linkedin.com/posts/endosound_dr-neil-sharmas-performing-outpatient-eus-activity-7383954759457628161-uLjx?utm_source=share&utm_medium=member_desktop&rcm=ACoAAADHxloB4yVfkiFYYjtD9A3ec2ECiZrDMqs

Most were trained to do EUS in hospitals. That paradigm is shifting. Dr. Neil Sharma recent presentation at Florida Live perhaps changes the calculus: many cases are safe in the ASC including imaging-only EUS and liver biopsies. Critically, CMS now reimburses up to $1,115 per case. Due to certa...

10/02/2025

Less than 24 hours remain to invest in EndoSound®.

We have already achieved milestones that few medtech companies reach this early: FDA clearance validating safety and effectiveness, reimbursement ensuring financial viability, and $1M in revenue generated since launch. Our physicians have completed more than 600 procedures with a 95 percent acceptance rate, and global demand is expanding through a $5M licensing deal. More than 350 investors have already joined us on Wefunder, committing over $1M.

This is the last opportunity to secure your stake before our campaign closes.
https://bit.ly/3K4S93O

09/30/2025

Only 3 days remain to join us on Wefunder.

Investors have already committed more than $2.3M, and momentum continues to build as we approach the close. Here are the top reasons they are backing EndoSound®:
✔️ FDA clearance and reimbursement already secured
✔️ $1M in revenue since launch
✔️ More than 600 procedures completed with a 95 percent clinical acceptance rate
✔️ A $5M licensing deal
✔️ Strong investor confidence with $2.3M+ raised in this current round

These milestones prove that we are beyond concept and already generating commercial traction with global demand. When the campaign closes in three days, the chance to invest at this stage will be gone.
https://bit.ly/3K4S93O

09/26/2025

Only one week remains to join us on Wefunder.
We have already reached milestones that few medtech companies achieve this early. FDA clearance validates safety and effectiveness, reimbursement secures financial viability for providers, and $1M in revenue since launch demonstrates commercial traction.

Investors have already committed more than $2.3M in this round, reflecting strong confidence in our mission to lower costs, expand access, and transform the $20B GI device market.

Our campaign closes in one week. Once it does, the chance to invest at today’s stage will be gone.

👉 Secure your stake now: https://bit.ly/3K4S93O

09/25/2025

WEBINAR TODAY!!: Inside the EndoSound® Investment: Lead Investor and EVS™ User reveal their perspectives.

Join us for "Inside the EndoSound® Investment: Lead Investor and EVS™ User, led by CEO, tell their perspectives".

Date: Thursday, September 25, 2025
Time: 4:30 - 5:30 EDT
Register: https://luma.com/uld2ofsg

Join EndoSound's CEO Scott Aldrich for an exclusive conversation with lead investor Chris Oubre and advisor/investor/physician Dr. Stuart Akerman. Discover why they believe in our mission, what drove their investment decisions, and how EndoSound is positioned to transform the future of healthcare. Stay for an interactive Q&A session with all three leaders.

If you've been on the fence about EndoSound, now is the time to act and learn more.

➡️ Register here: https://luma.com/uld2ofsg

We are Closing Soon!! Join EndoSound's CEO Scott Aldrich for an exclusive conversation with lead investor Chris Oubre and advisor/investor/physician Dr. Stuart…

09/23/2025

We’ve passed an exciting milestone on Wefunder: more than $1M raised from over 350+ investors who believe in EndoSound®. With FDA clearance, reimbursement, $1M in revenue since launch, 600+ completed procedures, and a $5M licensing deal secured, the momentum is undeniable.

We are just 10 days from closing our round on Wefunder!. This is the time to step in and be part of our mission to make advanced GI care more accessible and affordable worldwide.. Help us cross the finish line and scale access to life-saving GI technology.

https://bit.ly/3K4S93O

09/22/2025

EndoSound® has already cleared the steepest hurdles in medtech. FDA clearance validates the safety and effectiveness of the system, while reimbursement ensures hospitals and clinics can perform procedures with financial viability.

These milestones, combined with $1 million in revenue since launch, more than 600 completed procedures, a 95 percent clinical acceptance rate, and a $5M licensing deal, demonstrate that the foundation for growth is already in place. Investors have contributed more than $2.3M in the current round and interest continues to build as commercialization accelerates.

The Wefunder campaign is Closing Soon, making this the moment to secure your stake in the future of GI care.
https://bit.ly/4gt7gAa

09/19/2025

The countdown has begun, and only two weeks remain to invest in EndoSound®.
We have already cleared the steep hurdles in medtech, including FDA clearance, validation of safety and effectiveness, and reimbursement ensuring financial viability for hospitals and clinics. Commercial traction is real, with $650K in launch revenue, more than 600+ completed procedures and growing, a 95 percent clinical acceptance rate, and a $5M licensing deal. Investors have already committed more than $2.3M in the current round.

When the campaign closes, the opportunity to join at this stage will be gone. This is the moment to act.
https://bit.ly/4gt7gAa

09/15/2025

The gastrointestinal device market is a $20B+ global opportunity. By transforming a standard endoscope into a powerful ultrasound system at a fraction of the cost, EndoSound® unlocks massive untapped demand and opens the door to global adoption.

Investors now have the chance to be part of a company who is expanding access to advanced GI care worldwide.

👉 Be part of scaling access https://bit.ly/3K4S93O